November 28, 2016 - By Michael Collier
In a report issued to clients and investors on 28 November, AstraZeneca PLC (LON:AZN) stock had its “Neutral” Rating kept by research analysts at JP Morgan Cazenove. They currently have a GBX 4600.00 price target on company. JP Morgan Cazenove’s target suggests a potential upside of 8.25% from the company’s last close price.
Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4911.37 average target is 15.28% above today’s (GBX 4260.2) stock price. AstraZeneca PLC has been the topic of 341 analyst reports since July 23, 2015 according to StockzIntelligence Inc. As per Wednesday, March 9, the company rating was maintained by Morgan Stanley. As per Thursday, November 17, the company rating was maintained by Berenberg. The stock of AstraZeneca plc (LON:AZN) has “Buy” rating given on Monday, February 1 by Deutsche Bank. The stock has “Buy” rating given by Bryan Garnier & Cie on Tuesday, October 4. Cantor Fitzgerald maintained the shares of AZN in a report on Thursday, November 10 with “Buy” rating. The firm has “Buy” rating by Deutsche Bank given on Friday, May 20. Shore Capital maintained AstraZeneca plc (LON:AZN) on Wednesday, November 9 with “Hold” rating. Jefferies maintained the shares of AZN in a report on Friday, October 28 with “Buy” rating. The stock has “Buy” rating given by Deutsche Bank on Friday, November 11. On Thursday, March 24 the stock rating was maintained by Barclays Capital with “Equal Weight”.
About 476,710 shares traded hands. AstraZeneca plc (LON:AZN) has risen 8.64% since April 28, 2016 and is uptrending. It has outperformed by 2.62% the S&P500.
Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 EPS, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.46 billion for 11.89 P/E if the $0.57 EPS becomes a reality. After $1.32 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.
AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 53.78 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 27.28 P/E ratio. The Firm has its activities in over 100 countries.
According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.
Another recent and important AstraZeneca plc (LON:AZN) news was published by Schaeffersresearch.com which published an article titled: “Analyst Upgrades: Apple Inc., AstraZeneca plc, and Ctrip.com International, Ltd.” on November 25, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.